Tech Company Financing Transactions
Areteia Therapeutics Funding Round
Bain Capital Life Sciences, Access Biotechnology and Arch Venture Partners invested in a $75 million Series A funding round for Areteia Therapeutics. The financing round was announced on 2/14/2024.
Transaction Overview
Company Name
Announced On
2/14/2024
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
50 Mountaintop Rd.
Bernardsville, NJ 07924
USA
Bernardsville, NJ 07924
USA
Phone
Undisclosed
Website
Email Address
Overview
Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners, whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jorge Bartolome
Chief Financial Officer
Chris Visioli
Chief Scientific Officer
Calman Prussin
VP - Bus. Development
Mark Kreston
VP - Bus. Development
Peter Wijngaard
VP - General Counsel
Chris Cox
VP - Human Resources
Richard Fires
VP - Regulatory Affairs
Lex Kay
Browse more venture capital transactions:
Prev: 2/14/2024: Fordefi venture capital transaction
Next: 2/14/2024: Vimly Benefits Solutions venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs